Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

DAURISMO™ Clinical Studies (glasdegib)


The efficacy of DAURISMO in combination with low-dose cytarabine was evaluated in a multicenter, open-label, randomized study (Study BRIGHT AML 1003, NCT01546038) that included 115 patients age 55 years or older with newly-diagnosed AML who met at least one of the following criteria: a) age ≥75 years, b) severe cardiac disease, c) baseline Eastern Cooperative Oncology Group (ECOG) performance status of 2, or d) baseline serum creatinine >1.3 mg/dL. Patients were randomized 2:1 to receive DAURISMO at a 100 mg daily dose with low-dose cytarabine 20 mg subcutaneously twice daily on days 1 to 10 of a 28-day cycle (N=77) or low-dose cytarabine alone (N=38) in 28-day cycles until disease progression or unacceptable toxicity. Patients were stratified by cytogenetic risk (good/intermediate or poor).

The baseline demographic and disease characteristics are shown in Table 6. The two treatment arms were generally balanced with respect to the baseline demographics and disease characteristics (see Table 6).

Table 6. Baseline Demographic and Disease Characteristics in Patients with AML
Demographic and Disease CharacteristicsDAURISMO With Low-Dose Cytarabine
Low-Dose Cytarabine Alone
Abbreviations: AML = acute myeloid leukemia; N = number of patients; ECOG PS = Eastern Cooperative Oncology Group Performance Status.
Baseline ECOG PS was not reported for one patient in the DAURISMO with low-dose cytarabine arm.
Median (Min, Max) (Years)77 (64, 92)76 (58, 83)
≥ 75 years N (%)47 (61)23 (61)
Sex, N (%)
Male59 (77)23 (61)
Female18 (23)15 (39)
Race, N (%)
White75 (97)38 (100)
Black or African American1 (1)0 (0)
Asian1 (1)0 (0)
Disease History, N (%)
De Novo AML38 (49)18 (47)
Secondary AML39 (51)20 (53)
Prior Hypomethylating Agent Use11 (14)6 (16)
ECOG PS*, N (%)
0 to 135 (46)20 (53)
241 (53)18 (47)
Cytogenetic Risk Status, N (%)
Good/Intermediate48 (62)21 (55)
Poor29 (38)17 (45)
Baseline Severe Cardiac Disease51 (66)20 (53)
Baseline Serum Creatinine >1.3 mg/dL15 (19)5 (13)

Efficacy was established on the basis of overall survival (OS) from the date of randomization to death from any cause. With a median follow-up of approximately 20 months, the DAURISMO with low-dose cytarabine arm was superior to low-dose cytarabine alone arm (Figure 1). The efficacy results are shown in Table 7. Improvement in OS was consistent across prespecified cytogenetic risk subgroups.

Table 7. Efficacy Results From BRIGHT AML 1003
Endpoint/Study PopulationDAURISMO With Low-Dose CytarabineLow-Dose Cytarabine Alone
Abbreviations: AML = acute myeloid leukemia; N = number of patients; OS = overall survival; CI = confidence interval; CR = complete response.
Hazard ratio (DAURISMO with low-dose cytarabine/low-dose cytarabine alone) based on the Cox Proportional hazards model stratified by cytogenetic risk.
1-sided p-value from log-rank test stratified by cytogenetic risk.
  Median survival, months (95% CI)8.3 (4.4, 12.2)4.3 (1.9, 5.7)
  Hazard ratio (95% CI)*0.46 (0.30, 0.71)
  CR rate (in %, 95% CI)18.2 (10.3, 28.6)2.6 (0.1, 13.8)

Figure 1. BRIGHT AML 1003 – Kaplan-Meier Plot of Overall Survival for Patients with AML

Figure 1

Abbreviations: CI = confidence interval; OS = overall survival; LDAC = low-dose cytarabine.

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event